# Benzydamine Oromucosal Solution in Oral Mucositis (BOOM)

> **NCT05055726** · PHASE4 · COMPLETED · sponsor: **Aziende Chimiche Riunite Angelini Francesco S.p.A** · enrollment: 100 (actual)

## Conditions studied

- Radiation-Induced Mucositis
- Head and Neck Cancer

## Interventions

- **DRUG:** Benzydamine Hydrochloride 0.15% w/v oromucosal solution

## Key facts

- **NCT ID:** NCT05055726
- **Lead sponsor:** Aziende Chimiche Riunite Angelini Francesco S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-06
- **Primary completion:** 2022-09-05
- **Final completion:** 2022-09-05
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2022-11-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05055726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05055726, "Benzydamine Oromucosal Solution in Oral Mucositis (BOOM)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05055726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*